Drug intelligence / Profile preview

IS-vac

Development stage: Unknown
Lead developer: German Cancer Research Center
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

IS-vac (Immune Stimulator vaccine) is an investigational adjuvant-based sham vaccine developed by the German Cancer Research Center (DKFZ). It consists of a 33% DMSO and isotonic saline solution emulsified in Montanide ISA 51 VG. In clinical trials, such as the Phase 2 STAR-VACC study, IS-vac is administered subcutaneously in combination with topical imiquimod (Aldara) as an active control/comparator (immune stimulator) against the IDH1-vac peptide vaccine in patients with newly diagnosed IDH1R132H-positive high-grade astrocytomas.

Other names: Immune stimulator

Beyond the preview

Go deeper on IS-vac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IS-vac.